HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
SRXH
SRx Health Solutions Inc.
There isn't enough reported data to score SRXH yet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
SRXH Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Unavailable |
SRXH's profitability is currently under pressure. There isn't enough data to rate its revenue, cash flow and balance sheet.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
SRXH PE Valuation
SRXH has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
SRXH Forward outlook
There aren't enough analyst estimates for SRXH to show an outlook.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
SRXH has the stronger earnings trend. Trailing diluted EPS is down 257% for HIMS versus SRXH down 143%.
SRXH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2024 | -$921.78 | +$1,209.78 |
| Q2 2024 | -$1,052.00 | +$1,412.00 |
| Q1 2024 | -$1,380.00 | +$1,181.78 |
| Q4 2023 | -$1,435.11 | +$1,185.33 |
| Q3 2023 | -$2,131.56 | +$234.66 |
| Q2 2023 | -$2,464.00 | -$293.33 |
| Q1 2023 | -$2,561.78 | -670% |
| Q4 2022 | -$2,620.44 | -$645.33 |
SRXH is still losing money, but far less than before: $921.78 per share over the past year, against $14,549.33 at its worst in early 2021.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the stronger quarterly revenue trend. Revenue is up 49% for HIMS versus down 53% for SRXH.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over SRXH on profitability, with a higher operating margin.
SRXH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $3.4M | -70% |
| Q1 2026 | $3.4M | -52% |
| Q4 2025 | $2.8M | -61% |
| Q2 2025 | $11.4M | +34% |
| Q1 2025 | $7.2M | -9.4% |
| Q4 2024 | $7.2M | +26% |
| Q3 2024 | $11.4M | -13% |
| Q2 2024 | $8.5M | -19% |
SRXH's revenue has slid since its 2022 peak: $3M last quarter, down 53% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -94% | +58 points |
| Q1 2026 | -53% | -38 points |
| Q4 2025 | -135% | -112 points |
| Q2 2025 | -152% | -144 points |
| Q1 2025 | -15% | +16 points |
| Q4 2024 | -23% | +200 points |
| Q3 2024 | -9.9% | +10 points |
| Q2 2024 | -8.5% | +16 points |
SRXH's operating margin was −94% last quarter, down 79 points from the same quarter a year ago.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
SRXH has the stronger cash trend. Its trailing FCF is down 12% versus its history, compared with HIMS at down 84%.
SRXH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q1 2026 | -$6.6M | -1858% |
| Q4 2025 | -$2.9M | -$1.7M |
| Q1 2025 | $377K | +$1.4M |
| Q4 2024 | -$1.2M | -220% |
| Q3 2024 | -$2.2M | -745% |
| Q2 2024 | $5K | -98% |
| Q1 2024 | -$1M | +$474K |
| Q4 2023 | $983K | +$3.6M |
SRXH has burned cash in most quarters: −$10M over the past year, against −$2M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over SRXH on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
SRXH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +65% | +222K shares |
| 1 year | +2706% | +542K shares |
| 3 years | +3654% | +547K shares |
SRXH has 562,284 diluted shares, up 2706% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q4 2022 | — |
| Q4 2021 | $327,000 |
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
SRXH Net Leverage
SRXH's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
SRXH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 22.1 | Oversold |
| Stochastic | 11.2 | Oversold |
SRXH's weekly RSI is 22 (oversold) and its Stochastic is 11 (oversold).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
SRXH PE vs Healthcare Sector
SRXH has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
SRXH has stronger trend alignment. HIMS is above 0 of 5 weekly averages versus SRXH above 0 of 3.
SRXH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.22 | 23% below |
| 20 week MA | $1.74 | 46% below |
| 50 week MA | $6.72 | 86% below |
SRXH is in a downtrend: it's below all three of its weekly moving averages, and 86% below its 50-week average.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS has the edge over SRXH on returns for 2026, with the stronger performance.
SRXH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2025 | $121.3 | $16.9 | -86% |
| 2026 YTD | $16.9 | $0.94 | -94% |
SRXH has finished every year since 2025 lower, and it's down 94% so far in 2026.